Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immutep Ltd.

http://www.immutep.com

Latest From Immutep Ltd.

Merck KGaA Cancer Deal-Making Spree Continues With PDS Tie-Up

PDS is getting rights to Merck's M9241, a tumor-targeting interleukin-12 fusion compound which is a key component, together with its own investigational HPV16-targeted immunotherapy, in a triple combination being studied to treat advanced HPV-positive cancers.

Deals Cancer

Teva's New CEO Francis Takes Over A Steadier – Though Still Rocky – Organization

Teva announced the appointment of former Sandoz CEO Richard Francis as its next leader as Kare Schultz steps down.

Leadership Business Strategies

The Journey Has Just Begun For LAG-3 Therapeutics

Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.

Innovation Research & Development

Gamida Set For Breakthrough Transplant Therapy Approval – But Cash Problems Could Hit Launch

With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.

Companies Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Immutep S.A.S.
    • Immutep GmbH
    • Immutep, U.S., Inc.
    • Prima BioMed Ltd.
UsernamePublicRestriction

Register